67828-44-8

Usage

Uses

Used in Pharmaceutical Industry:
2,4-DIHYDROXY-5-CHLOROBENZOIC ACID is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its presence in the molecular structure of certain drugs aids in their therapeutic effects, making it an essential component in the development of new medications.
Used in Dye Industry:
In the dye industry, 2,4-DIHYDROXY-5-CHLOROBENZOIC ACID is utilized as a precursor in the production of dyes. Its chemical properties contribute to the color and stability of the dyes, which are then used in various applications such as textiles, plastics, and printing inks.
Used in Agriculture:
2,4-DIHYDROXY-5-CHLOROBENZOIC ACID is used as a herbicide due to its herbicidal properties. It helps control the growth of unwanted plants, thereby improving crop yield and quality.
Used in Antimicrobial Applications:
2,4-DIHYDROXY-5-CHLOROBENZOIC ACID exhibits antimicrobial properties, making it useful in industrial applications where controlling the growth of microorganisms is essential, such as in the production of food, cosmetics, and medical devices.
Used in Antioxidant and Anti-inflammatory Research:
2,4-DIHYDROXY-5-CHLOROBENZOIC ACID is studied for its potential antioxidant and anti-inflammatory properties. Its ability to combat oxidative stress and reduce inflammation has shown promise for use in the development of new medications, particularly for conditions associated with chronic inflammation and oxidative damage.

InChI:InChI=1/C7H5ClO4/c8-4-1-3(7(11)12)5(9)2-6(4)10/h1-2,9-10H,(H,11,12)

Upstream product

• 89-86-1 4-hydroxysalicylic acid 
• 23053-75-0 4-Chlor-6-chloracetylresorcin-dimethylether 
• 7791-25-5 sulfuryl dichloride 
• 60-29-7 diethyl ether 
• 7782-50-5 chlorine 
• 64-19-7 acetic acid 
• 95-88-5 4-Chlororesorcinol 
• 7732-18-5 water 
• 829-20-9 2',4'-dimethoxyacetophenone 
• 108-46-3 recorcinol 
• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 1378866-39-7 5-chloro-2-hydroxy-4-methoxybenzoic acid 
• 67828-69-7 methyl 5-chloro-2,4-dihydroxybenzoate 

Downstream Products

• 99854-28-1 3-butyryl-5-chloro-2,4-dihydroxy-benzoic acid 
• 95-88-5 4-Chlororesorcinol 
• 102541-32-2 5-chloro-2,4-dihydroxy-3-propionyl-benzoic acid 
• 67828-69-7 methyl 5-chloro-2,4-dihydroxybenzoate 
• 97028-38-1 3,3'-dichloro-2,2',4,4'-tetrahydroxybenzophenone 
• 854261-04-4 1-(2-methoxy-3,6-bis(methoxymethoxy)-5-nitrophenyl)propan-2-yl 5-chloro-2,4-dihydroxy benzoate 
• 913622-60-3 1-(2-methoxy-3,6-bis(methoxymethoxy)phenyl)propan-2-yl 5-chloro-2,4-dihydroxybenzoate 
• 913622-56-7 1-(2-methoxy-6-(methoxymethoxy)phenyl)propan-2-yl 5-chloro-2,4-dihydroxybenzoate 
• 913621-96-2 2,3,6-trimethoxy-5-nitrophenethyl 5-chloro-2,4-dihydroxybenzoate 
• 913621-98-4 1-(2,3,6-trimethoxy-5-nitro)prop-2-yl 5-chloro-2,4-dihydroxybenzoate 
• 913621-97-3 3-(2,3,6-trimethoxy-5-nitro)propyl 5-chloro-2,4-dihydroxybenzoate 
• 884646-74-6 2-methoxy-3,6-bis(methoxymethoxy)-5-nitrophenethyl 5-chloro-2,4-dihydroxybenzoate 
• 913622-14-7 3-(2-methoxy-3,6-bis(methoxymethoxy)-5-nitrophenyl)propyl 5-chloro-2,4-dihydroxybenzoate 
• 913622-15-8 1-(2-methoxy-3,6-bis(methoxymethoxy)-5-nitrophenyl)pentan-2-yl 5-chloro-2,4-dihydroxybenzoate 

Relevant academic research and scientific papers

NOVEL COMPOUND HAVING HSP90 INHIBITORY ACTIVITY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MEDICAL USE THEREOF

The present invention relates to a novel compound having HSP90 inhibitory activity or a pharmaceutically acceptable salt thereof, and a medicinal use thereof, and composition comprising a dihydroxyphenyl compound or a benzamide compound, which is a novel compound having the HSP90 inhibitory activity of the present invention can effectively inhibit HSP90, and thus can be usefully used as a pharmaceutical composition for preventing or treating HSP90-mediated diseases or a health functional food for preventing or improving HSP90-mediated diseases, which selected from the group consisting of cancer diseases, degenerative neurological diseases and viral infections.

Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors

Heat shock protein 90 (Hsp90) is a ubiquitous molecular chaperone that is responsible for the stabilization and maturation of many oncogenic proteins. Therefore, Hsp90 has emerged as an attractive target in the field of cancer chemotherapy. In this study, we report the design, synthesis, and biological evaluation of a series of Hsp90 inhibitors. In particular, compound 30f shows a significant Hsp90α inhibitory activity with IC50 value of 5.3 nM and an excellent growth inhibition with GI50 value of 0.42 μM against non-small cell lung cancer cells, H1975. Compound 30f effectively reduces the expression levels of Hsp90 client proteins including Her2, EGFR, Met, Akt, and c-Raf. Consequently, compound 30f promotes substantial cleavages of PARP, Caspase 3, and Caspase 8, indicating that 30f induces cancer cell death via apoptotic pathway. Moreover, cytochrome P450 assay indicates that compound 30f has weak inhibitory effect on the activities of five major P450 isoforms (IC50 > 5 μM for 1A2, 2C9, 2C19, 2D6, and 3A), suggesting that clinical interactions between 30f and the substrate drugs of the five major P450 isoforms are not expected. Compound 30f also inhibits the tumor growth in a mouse xenograft model bearing subcutaneous H1975 without noticeable abnormal behavior and body weight changes. The immunostaining and western immunoblot analysis of EGFR, Met, Akt in xenograft tissue sections of tumor further demonstrate a good agreement with the in vitro results.

Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide

The molecular chaperone Hsp90 plays an important role in cancer cell survival and proliferation by regulating the maturation and stabilization of numerous oncogenic proteins. Due to its potential to simultaneously disable multiple signaling pathways, Hsp90 has emerged as an attractive therapeutic target for cancer treatment. In this study, the design, synthesis, and biological evaluation of a series of Hsp90 inhibitors are described. Among the synthetic compounds, 6,7-dihydrothieno [3,2-c]pyridin-5(4H)-yl amide 19 exhibits a remarkable binding affinity to the N-terminus of Hsp90 in a fluorescence polarization (FP) binding assay (IC50= 50.3 nM). Furthermore, it effectively inhibits the proliferation of H1975 non-small cell lung cancer (NSCLC) and Skbr3 breast cancer cell lines with GI50values of 0.31 μM and 0.11 μM, respectively. Compound 19 induces the degradation of the Hsp90 client proteins including EGFR, Her2, Met, c-Raf, and Akt, and consequently promotes apoptotic cancer cell death. Compound 19 also inhibits the growth of H1975 xenografts in NOD-scid IL2R gammanullmice without any apparent body-weight loss. The immunohistologic evaluation indicates that compound 19 decreases the expression of Akt in xenograft tumor tissue via an inhibition of the Hsp90 chaperon function. Additionally, the cytochrome P450 assay indicates that compound 19 has no effect on the activities of five major P450 isoforms (IC50> 50 μM for 1A2, 2C9, 2C19, 2D6, and 3A), suggesting that clinical interactions between compound 19 and the substrate drugs of the five major P450 isoforms are not expected. Overall, compound 19 represents a new class of Hsp90 inhibitor with its 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl-amide structure, and it has the therapeutic potential to overcome drug resistance in cancer chemotherapy.

NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of formula (I) wherein R1, R3, R4, R5, R6, R7, and R10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.

Heat shock protein 90 inhibitors

Novel compounds useful for inhibiting the 90 kDa heat shock proteins containing a quinone-like moiety and a di-hydroxy phenol like moiety, similar to geldanamycin and radicicol.

Radester, a novel inhibitor of the Hsp90 protein folding machinery

(Chemical Equation Presented) The antitumor antibiotics radicicol and geldanamycin are potent inhibitors of the Hsp90 protein folding machinery. Radester is a hybrid composed of radicicol's resorcinol ring and geldanamycin's quinone through an isopropyl ester. Radester was prepared, and the cytotoxicity of it and the corresponding hydroquinone were determined in MCF-7 breast cancer cells to be 13.9 and 7.1 μM, respectively. Protein degradation assays were performed on Hsp90-dependent client proteins, Her-2 and Raf, to correlate Hsp90 inhibition to cytotoxicity.